设为首页  |  加入收藏
 
 首页  关于我们  团队队伍  旗下产业  研究生教育  实践教学  党群工作  员工工作  员工园地  下载中心 
中药学
 研究生专业领域 
 研究生招生 
 硕士生导师 
 公司产品 
中药学  
当前位置: 首页>>研究生教育>>硕士生导师>>中药学>>正文
庄涛
2023-02-22 13:08  

姓名:庄涛

性别:男

职称:校聘副教授

职务:硕士生导师

学历学位:博士研究生

人简介:

201406月毕业于中国药科大学天然药物化学专业,获工学硕士学位

201407月至201708月江苏恩华药业股份有限公司,新药研发

202112月毕业于华中科技老员工物医学工程专业,获工学博士学位

20219月至今 威斯尼斯人老品牌官网(中国)有限公司

庄涛,博士研究生,威斯尼斯人老品牌官网(中国)有限公司校聘副教授、硕士生导师。长期从事新型镇痛药物、麻醉药物与抗抑郁药物研究;新型晶态固体/复方药物研究;药物结构解析与质量控制等研究工作。曾参与三十多个创新药、仿制药项目的研究与申报工作。与中国药科大学、湖南师范大学、中科院昆明植物所、大生命科学(武汉)有限公司等单位建立了良好的科学研究和创新合作关系。主持江苏省海洋药物活性分子筛选重点实验室开放基金(HY202207)、江苏省优势学科“海洋科学”创新子课题(2022JSPAPD006)、威斯尼斯人老品牌官网人才引进项目等,以第一作者或通讯作者在European Journal of Medicinal Chemistry、Bioorganic Chemistry、Psychopharmacology、Biomedicines、Journal of Pharmaceutical and Biomedical Analysis、New Journal of Chemistry等SCI期刊上发表研究论文10余篇。

课程教学:

《药学前沿》

主要研究方向介绍:

1)新型镇痛药物、麻醉药物与抗抑郁药物研究:以临床需求为导向,基于Sigma-1受体、组胺H3受体、单胺转运体、GABAA等新型靶点的创新药物研发,打造独具特色的创新药物研发生态体系;

2)新型晶态固体/复方药物研究:基于多靶点药物治疗理念,研究不同作用机理药物间的协同作用,通过前药技术、纳米技术、共晶技术开发新型晶态固体/复方药物;

3)药物结构解析与质量控制:针对是药物研究过程中“杂质研究”的难点问题以质量源于设计(QbD)为导向,以结构解析为手段,为药物工艺开发、杂质控制、处方优化提供有力支撑。

主要研究项目:

1.基于sigma-1受体/μ受体双靶点的新型抗神经痛药物研究,威斯尼斯人老品牌官网人才引进科研基金项目,2022-2025年,项目负责人;

2.基于σ1受体/组胺H3受体双靶点协同作用的新型抗神经痛药物研究,江苏省海洋药物活性分子筛选重点实验室开放课题,2022-2024年,项目负责人。

代表性著作:

[1] Tao Zhuang, Jiaying Xiong, Xia Ren, Lingzhi Liang, Zhaoyang Qi, Shuang Zhang, Wei Du, Yin Chen, Xin Liu, Guisen Zhang. Benzylaminofentanyl derivatives: Discovery of bifunctional μ-opioid and σ1 receptor ligands as novel analgesics with reduced adverse effects. European Journal of Medicinal Chemistry, 2022, 241: 114649. (IF = 7.088,第一作者)

[2] Tao Zhuang, Jiaying Xiong, Shuaishuai Hao, Wei Du, Zhenming Liu, Bifeng Liu, Guisen Zhang, Yin Chen. Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. European Journal of Medicinal Chemistry, 2021, 223: 113658. (IF = 7.088,第一作者)

[3] Ziying Li, Xinyi Xiao, Yulin Xue, Huiling Zhou, Chaonan Huang, Mo Zhu, Tao Zhuang*, Yin Chen and Ling Huang. Discovery of a new class of benzoxazole derivatives as histamine H3 receptor ligands for treating neuropathic pain. Bioorganic Chemistry, 2022, 127: 106039. (IF = 5.307,第一通讯作者)
[4] Jiaying Xiong#, Tao Zhuang#, Yurong Ma, Junyi Xu, Jiaqi Ye, Ru Ma, Shuang Zhang, Xin Liu, Bi-Feng Liu, Chao Hao, Guisen Zhang, Yin Chen. Optimization of bifunctional piperidinamide derivatives as σ1R antagonists/MOR agonists for treating neuropathic pain. European Journal of Medicinal Chemistry, 2021, 226: 113879. (IF = 7.088,共同第一作者)

[5] Yanming Chen, Xinyi Xiao, Chaonan Huang, Jin Zhu, Huiling Zhou, Huimin Qin, Yu Bao, Tao Zhuang*, Guisen Zhang*. Flupirtine and antihistamines exert synergistic anti-nociceptive effects in mice. Psychopharmacology, 2023, https://doi.org/10.1007/s00213-023-06329-3. (IF = 4.415,第一通讯作者)

[6] Yurong Ma, Wenwen Liu, Lingzhi Liang, Jiaqi Ye, Chaonan Huang, Tao Zhuang*, Guisen Zhang*. Synergistic Antinociceptive Effects of Indomethacin-Pregabalin and Meloxicam-Pregabalin in Paclitaxel-Induced Neuropathic Pain, Biomedicines, 2022, 10(6), 1413. (IF = 6.081,第一通讯作者)

[7] Chenxin Duan, Yanming Chen, Yuxin Zhang, Feifei Liang, Wenwen Liu, Xinyi Xiao, Cangcang Xu, Tao Zhuang*, Chao Hao and Yin Chen. Two Cocrystals of Olaparib with Flavonoids toward Sustained-Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis. Crystal Growth & Design, 2022, 22, 8, 4885–4894. (IF =4.010,第一通讯作者)

[8] Tao Zhuang, Jian Jin, Yurong Ma, Xia Ren, Lingzhi Liang, Wei Du, Bifeng Liu, Xin Liu and Guisen Zhang. Structural elucidation and synthesis of a dimeric degradation impurity during long-term stability studies of oxycodone hydrochloride injection. New Journal of Chemistry, 2021, 45, 18651-18658. (IF = 3.925,第一作者)

[9] Huiling Zhou, Chenxin Duan, Huimin Qin, Chaonan Huang, Jiangxuan Hou, Yanming Chen, Jin Zhu, Cangcang Xu, Jian Jin, Tao Zhuang*. Synthesis and structural characterization of a novel palbociclib-kaempferol cocrystal with improved tabletability and synergistic antitumor activity. Journal of Molecular Structure, 2023, 1281, 135101. (IF = 3.841,最后通讯作者)

[10] Feifei Liang, Xiaofang Tan, Shuaishuai Hao, Wenwen Liu, Chenxin Duan, Guisen Zhang, Tao Zhuang*, Yin Chen, Chao Hao. Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate, Journal of Molecular Structure, 1225 (2022) 132340. (IF = 3.841,第一通讯作者)

[11] Jin Zhu, Xinyi Xiao, Huimin Qin, Zhengkang Luo, Yanming Chen, Chaonan Huang, Xue Jiang, Shuxian Liu, Tao Zhuang*, Guisen Zhang. Design, synthesis and evaluation of heterocyclic 2- phenyacetate derivatives as water-soluble rapid recovery hypnotics. Bioorganic & Medicinal Chemistry Letters, 2023, 82, 129165. (IF = 2.940,第一通讯作者)

[12] Zhaoyang Qi, Ziying Li, Mo Zhu, Xiaohua Zhang, Guisen Zhang, Tao Zhuang*, Yin Chen, Ling Huang. Design, synthesis, and evaluation of phenylpiperazine-phenylacetate derivatives as rapid recovery hypnotic agents. Bioorganic & Medicinal Chemistry Letters, 2022, 57, 128497. (IF = 2.940,第一通讯作者)

[13] Tao Zhuang, Yin Chen, Junyi Xu, Zhaoyang Qi, Jiaqi Ye, Cangcang Xu, Wei Du, Bifeng Liu, Guisen Zhang, Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium, Journal of Pharmaceutical and Biomedical Analysis, 2021, 200, 114072. (IF = 3.571,第一作者)

[14] Tao Zhuang, Wen Zhang, Longji Cao, Kai He, Yu Wang, Jing Li, Liang Chen, Bifeng Liu, Guisen Zhang, Isolation, identification and characterization of two novel process-related impurities in olanzapine, Journal of Pharmaceutical and Biomedical Analysis, 2018, 152,188–196. (IF = 3.571,第一作者)

[15] 庄涛,李子颖,陈寅,黄超男,陈衍铭,一种苯甲酰胺类衍生物及其制备方法和应用,中国发明专利,CN114478360A
[16] 张桂森,庄涛,陈寅,杜伟,刘笔锋,4-酰胺哌啶类衍生物及其制备方法和应用,中国发明专利, CN114763335A
[17]
庄涛,马玉蓉,张桂森,一种可治疗疼痛的药物组合及其应用,中国发明专利, CN114404409A
[18]
庄涛,黄超男,朱瑾,张桂森,一种用于预防或治疗疼痛的药物组合物,中国发明专利, CN 115364229A

联系方式:

话:15852168047

电子邮箱:zhuang_tao@jou.edu.cn


(2022年7月更新)

关闭窗口

威斯尼斯人老品牌官网(中国)有限公司 版权所有 地址:江苏省连云港市海州区苍梧路59号
电话:0518-85895791  邮编:222005